Polycystic ovary syndrome and risks for COVID-19 infection: A comprehensive review : PCOS and COVID-19 relationship

Rev Endocr Metab Disord. 2022 Apr;23(2):251-264. doi: 10.1007/s11154-022-09715-y. Epub 2022 Feb 26.

Abstract

This comprehensive review aimed to evaluate the relationship between SARS-CoV-2 infection (the cause of coronavirus disease 2019, or COVID-19) and the metabolic and endocrine characteristics frequently found in women with polycystic ovary syndrome (PCOS). In the general population, COVID-19 is more severe in subjects with dyslipidemia, obesity, diabetes mellitus, and arterial hypertension. Because these conditions are comorbidities commonly associated with PCOS, it was hypothesized that women with PCOS would be at higher risk for acquiring COVID-19 and developing more severe clinical presentations. This hypothesis was confirmed in several epidemiological studies. The present review shows that women with PCOS are at 28%-50% higher risk of being infected with the SARS-CoV-2 virus at all ages and that, in these women, COVID-19 is associated with increased rates of hospitalization, morbidity, and mortality. We summarize the mechanisms of the higher risk of COVID-19 infection in women with PCOS, particularly in those with carbohydrate and lipid abnormal metabolism, hyperandrogenism, and central obesity.

Keywords: COVID-19; Dyslipidemia; Hyperandrogenism; Insulin resistance; Obesity; Polycystic ovary syndrome.

Publication types

  • Review

MeSH terms

  • COVID-19* / epidemiology
  • Female
  • Humans
  • Hyperandrogenism* / epidemiology
  • Insulin Resistance*
  • Polycystic Ovary Syndrome* / complications
  • Polycystic Ovary Syndrome* / epidemiology
  • Polycystic Ovary Syndrome* / metabolism
  • SARS-CoV-2